Active substanceMethyl ethylpyridinolMethyl ethylpyridinol Similar drugsTo uncover Cardiocipine solution d / infusion BIOSINTEZ, PAO Russia Cardiocipine solution w / m in / in BIOSINTEZ, PAO Russia Methyl ethylpyridinol solution for injections ATOLL, LLC Russia Methyl ethylpyridinol solution for injections ELLARA, LTD. Russia Methyl ethylpyridinol solution for injections Company DEKO, LLC Russia Methyl ethylpyridinol-Eskom solution for injections ESKOM NPK, OAO Russia Emoticon Optics drops d / eye SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia Emoxibel solution d / infusion Emoxibel solution for injections BELMEDPREPARATY, RUP Republic of Belarus Emoxibel drops d / eye BELMEDPREPARATY, RUP Republic of Belarus Emoxibel solution w / m in / in BELMEDPREPARATY, RUP Republic of Belarus Emoxipine® drops d / eye MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine solution w / m in / in MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine drops d / eye FARMENT FIRM, LLC Russia Emoxipine solution for injections MOSCOW ENDOCRINE FACTORY, FSUE Russia Emoxipine-AKOS drops d / eye SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products Russia Emoxipine-Acti solution d / infusion Aktifarm, OOO Russia Dosage form: & nbspEye drops. Composition:per ml: active substance: methyl ethylpyridinol hydrochloride (emoxipin) - 10 mg; Excipients: sodium sulphite - 3 mg, sodium benzoate - 2 mg, potassium dihydrogen phosphate - 6.2 mg, sodium hydrogen phosphate dodecahydrate -7,5 mg, water for injection - up to 1 ml. Description:Transparent colorless or yellow liquid. Pharmacotherapeutic group:Antioxidant. ATX: & nbspS.01.X.A Other drugs for the treatment of eye diseases Pharmacodynamics:Antioxidant (a drug that prevents the lipid peroxidation of cell membrane lipids), which possesses angioprotective (vascular stability), antiaggregatory (preventing platelet adhesion) and antihypoxic (increasing tissue resistance to oxygen deficiency) activity.Reduces the permeability of capillaries and strengthens the vascular wall (angioprotector). Reduces blood viscosity and platelet aggregation (antiaggregant). The inhibitor of free-radical processes, has a membrane-stabilizing action.Has retinoprotective properties, protects the retina and other eye tissues from the damaging effect of high-intensity light.Promotes resorption of intraocular hemorrhages, reduces blood clotting, improves microcirculation of the eye. Stimulates reparative processes in the cornea (including in the early postoperative and post-natal period). Pharmacokinetics:Quickly penetrates into the tissues of the eye, where it is deposited and metabolized. In the tissues of the eye, the concentration is higher than in the blood. There were 5 metabolites, represented by dealkylated and conjugated metabolic products. Metabolised in the liver. In significant quantities, an active metabolite of 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in the liver. Further in the blood under the influence of alkaline phosphatase there is a splitting of 2-ethyl-6-methyl-3-hydroxypyridinaphosphate into phosphoric acid and 3-hydroxypyridine. Metabolites are excreted by the kidneys. Indications:It is used in adults with the following diseases and conditions:- subconjunctival and intraocular hemorrhages of various genesis; - injury, inflammation and burn of the cornea; -dystrophic diseases of the cornea; -complicated myopia;-protection of the cornea (when wearing contact lenses). Contraindications:Hypersensitivity to the components of the drug, pregnancy, lactation, children under 18 years. Pregnancy and lactation:The drug is contraindicated in pregnancy.If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped. Dosing and Administration:The drug is instilled in the conjunctival sac 1-2 drops 2-3 times a day.The duration of the course of treatment depends on the course of the disease (usually 3-30 days) and is determined by the doctor. In the presence of indications and good tolerability, the duration of treatment can be up to 6 months. Repeated courses of treatment can be conducted 2-3 times a year.Recommendations for the use of vials with dropper caps: before using the drug, remove the aluminum cap from the bottle, remove the rubber stopper and close the bottle with a dropper, previously released from the package. Then remove the cap from the cap-dropper, turn the bottle, drip the required number of drops of the drug. After applying the bottle, return to the vertical position and put the cap on the lid-dropper. Side effects:Burning sensation, itching in the eye, short-term conjunctival hyperemia, rarely: local allergic reactions. Overdose:Not described. Interaction:The drug should not be mixed with other drugs. Special instructions:Before instillation, soft contact lenses should be removed, the lenses can be re-applied no earlier than 20 minutes.If it is necessary to simultaneously apply other eye drops, the drug should be instilled by the patient not earlier than 15 minutes after the complete absorption of the previous drug. Effect on the ability to drive transp. cf. and fur:Influence on the management of vehicles or work with complex equipment is not described. Form release / dosage:Eye drops 1%. Packaging:5 ml in bottles.On 1 bottle together with a lid-dropper and instructions for use are placed in a pack of cardboard. Storage conditions:In the dark place at a temperature of no higher than 25 ° C.Keep out of the reach of children. Shelf life:3 years.After opening, the bottle should be stored at a temperature of no higher than 25 ° C for 4 weeks. Do not use after the expiration date. Terms of leave from pharmacies:On prescription Registration number:LP-000020 Date of registration:28.10.2010 / 26.05.2016 Expiration Date:Unlimited The owner of the registration certificate:BELMEDPREPARATY, RUP BELMEDPREPARATY, RUP Republic of Belarus Manufacturer: & nbspBELMEDPREPARATY, RUP Republic of Belarus Information update date: & nbsp2016-08-27 Illustrated instructions × Illustrated instructions Instructions